Literature DB >> 34550662

Comparison between Veteran and Non-Veteran Populations with Clinical Stage I Non-Small Cell Lung Cancer Undergoing Surgery.

Brendan T Heiden1, Daniel B Eaton2, Su-Hsin Chang2,3, Yan Yan2,3, Martin W Schoen2, Mayank R Patel2, Daniel Kreisel1,2, Ruben G Nava1,2, Bryan F Meyers1, Benjamin D Kozower1, Varun Puri1,2.   

Abstract

OBJECTIVE: The aim of this study was to compare quality of care and outcomes between Veteran and non-Veteran patients undergoing surgery for clinical stage I non-small cell lung cancer (NSCLC).
BACKGROUND: Prior studies and the lay media have questioned the quality of care that Veterans with lung cancer receive through the Veterans Health Administration (VHA). We hypothesized Veterans undergoing surgery for early-stage NSCLC receive high quality care and have similar outcomes compared to the general population.
METHODS: We performed a retrospective cohort study of patients with clinical stage I NSCLC undergoing resection from 2006 to 2016 using a VHA dataset. Propensity score matching for baseline patient- and tumor-related variables was used to compare operative characteristics and outcomes between the VHA and the National Cancer Database (NCDB).
RESULTS: The unmatched cohorts included 9,981 VHA and 176,304 NCDB patients. The VHA had more male, non-white patients with lower education levels, higher incomes, and higher Charlson/Deyo scores. VHA patients had inferior unadjusted 30-day mortality (VHA 2.1% vs NCDB 1.7%, p = 0.011) and median overall survival (69.0 vs 88.7 months, p < 0.001). In the propensity matched cohort of 6,792 pairs, VHA patients were more likely to have minimally invasive operations (60.0% vs 39.6%, p < 0.001) and only slightly less likely to receive lobectomies (70.1% vs 70.7%, p = 0.023). VHA patients had longer lengths of stay (8.1 vs 7.1 days, p < 0.001) but similar readmission rates (7.7% vs 7.0%, p = 0.132). VHA patients had significantly better 30-day mortality (1.9% vs 2.8%, p < 0.001) and median overall survival (71.4 vs 65.2 months, p < 0.001).
CONCLUSIONS: Despite having more comorbidities, Veterans receive exceptional care through the VHA with favorable outcomes, including significantly longer overall survival, compared to the general population. Copyright (C) 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 34550662      PMCID: PMC8581073          DOI: 10.1097/SLA.0000000000004928

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  34 in total

1.  Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration.

Authors:  Mary Beth Landrum; Nancy L Keating; Elizabeth B Lamont; Samuel R Bozeman; Barbara J McNeil
Journal:  Cancer       Date:  2011-11-09       Impact factor: 6.860

2.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

3.  Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System: 2010 Update.

Authors:  Leah L Zullig; Kellie J Sims; Rebecca McNeil; Christina D Williams; George L Jackson; Dawn Provenzale; Michael J Kelley
Journal:  Mil Med       Date:  2017-07       Impact factor: 1.437

4.  Practical Guide to Surgical Data Sets: Society of Thoracic Surgeons (STS) National Database.

Authors:  Farhood Farjah; Amy H Kaji; Danny Chu
Journal:  JAMA Surg       Date:  2018-10-01       Impact factor: 14.766

5.  Colorectal Cancer Statistics From the Veterans Affairs Central Cancer Registry.

Authors:  Leah L Zullig; Valerie A Smith; George L Jackson; Susanne Danus; Merritt Schnell; Jennifer Lindquist; Dawn Provenzale; Morris Weinberger; Michael J Kelley; Hayden B Bosworth
Journal:  Clin Colorectal Cancer       Date:  2016-05-07       Impact factor: 4.481

6.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Authors:  Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

7.  Wait times for cancer surgery in the United States: trends and predictors of delays.

Authors:  Karl Y Bilimoria; Clifford Y Ko; James S Tomlinson; Andrew K Stewart; Mark S Talamonti; Denise L Hynes; David P Winchester; David J Bentrem
Journal:  Ann Surg       Date:  2011-04       Impact factor: 12.969

8.  Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy.

Authors:  Pamela Samson; Varun Puri; Stephen Broderick; G Alexander Patterson; Bryan Meyers; Traves Crabtree
Journal:  Ann Thorac Surg       Date:  2016-12-23       Impact factor: 4.330

Review 9.  Lung and colorectal cancer treatment and outcomes in the Veterans Affairs health care system.

Authors:  Leah L Zullig; Christina D Williams; Alice G Fortune-Britt
Journal:  Cancer Manag Res       Date:  2015-01-14       Impact factor: 3.989

10.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.

Authors:  Peter C Austin
Journal:  Stat Med       Date:  2009-11-10       Impact factor: 2.373

View more
  3 in total

1.  Keeping a Safe Distance From Surgical Volume Standards.

Authors:  Brendan T Heiden; Benjamin D Kozower
Journal:  J Clin Oncol       Date:  2022-01-24       Impact factor: 50.717

2.  The Impact of Persistent Smoking After Surgery on Long-term Outcomes After Stage I Non-small Cell Lung Cancer Resection.

Authors:  Brendan T Heiden; Daniel B Eaton; Su-Hsin Chang; Yan Yan; Martin W Schoen; Li-Shiun Chen; Nina Smock; Mayank R Patel; Daniel Kreisel; Ruben G Nava; Bryan F Meyers; Benjamin D Kozower; Varun Puri
Journal:  Chest       Date:  2021-12-14       Impact factor: 10.262

3.  Assessment of Duration of Smoking Cessation Prior to Surgical Treatment of Non-small Cell Lung Cancer.

Authors:  Brendan T Heiden; Daniel B Eaton; Su-Hsin Chang; Yan Yan; Martin W Schoen; Li-Shiun Chen; Nina Smock; Mayank R Patel; Daniel Kreisel; Ruben G Nava; Bryan F Meyers; Benjamin D Kozower; Varun Puri
Journal:  Ann Surg       Date:  2021-11-18       Impact factor: 13.787

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.